These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

211 related articles for article (PubMed ID: 830742)

  • 21. The rabbit properdin system: I. Identification of a new factor and purification of rabbit properdin.
    Naff GB; Hedrick SW; Ratnoff WD; Novak MA; Smith MC; Steiner C; Todd EW
    J Immunol; 1980 Jun; 124(6):2625-31. PubMed ID: 6900053
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Alternative pathway of complement: demonstration and characterization of initiating factor and its properdin-independent function.
    Schreiber RD; Götze O; Müller-Eberhard HJ
    J Exp Med; 1976 Oct; 144(4):1062-75. PubMed ID: 62010
    [TBL] [Abstract][Full Text] [Related]  

  • 23. The reaction of zymosan with the properdin system: isolation of purified factor D from guinea pig serum and study of its reaction characteristics.
    Brade V; Nicholson A; Lee GD; Mayer MM
    J Immunol; 1974 May; 112(5):1845-54. PubMed ID: 4818461
    [No Abstract]   [Full Text] [Related]  

  • 24. A new activity of complement component C3: cell-bound C3b potentiates lysis of erythrocytes by C5b,6 and terminal components.
    Hammer CH; Abramovitz AS; Mayer MM
    J Immunol; 1976 Sep; 117(3):830-4. PubMed ID: 956655
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Mechanism of complement inactivation by glycoprotein C of herpes simplex virus.
    Kostavasili I; Sahu A; Friedman HM; Eisenberg RJ; Cohen GH; Lambris JD
    J Immunol; 1997 Feb; 158(4):1763-71. PubMed ID: 9029114
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Chemotactic activity derived from interaction of factors D and B of the properdin pathway with cobra venom factor or C3B.
    Ruddy S; Austen KF; Goetzl EJ
    J Clin Invest; 1975 Mar; 55(3):587-92. PubMed ID: 1167871
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Receptors on guinea-pig erythrocytes specific for cell-bound fourth component of human complement (C4).
    Wilson AB; Prichard-Thomas S; Lachmann PJ; Coombs RR
    Immunology; 1980 Feb; 39(2):195-202. PubMed ID: 7380467
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Properdin: initiation of alternative complement pathway.
    Fearon DT; Austen KF
    Proc Natl Acad Sci U S A; 1975 Aug; 72(8):3220-4. PubMed ID: 1059108
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Inhibition of immune precipitation by complement.
    Hong K; Takata Y; Sayama K; Kozono H; Takeda J; Nakano Y; Kinoshita T; Inoue K
    J Immunol; 1984 Sep; 133(3):1464-70. PubMed ID: 6747294
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Comparison of the effect of various antisera and cobra venom factor on inflammatory reactions in guinea-pig skin. I. Non-specific inflammation due to the intradermal injection of turpentine.
    Lewis E; Turk JL
    J Pathol; 1975 Feb; 115(2):97-109. PubMed ID: 1080193
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Properdin- and nephritic factor-dependent C3 convertases: requirement of native C3 for enzyme formation and the function of bound C3b as properdin receptor.
    Schreiber RD; Medicus RG; Gïtze O; Müller-Eberhard HJ
    J Exp Med; 1975 Sep; 142(3):760-72. PubMed ID: 1165475
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Improved efficiency of mouse, guinea pig and human C3b inactivator at low ionic strength, and reproducible immune-adherence with mouse complement.
    Linscott WD; Triglia RP
    J Immunol Methods; 1977; 15(2):121-9. PubMed ID: 845446
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Potentiation of antiboty-dependent cell-mediated cytotoxicity by target cell-bound C3b.
    Ghebrehiwet B; Medicus RG; Müller-Eberhard HJ
    J Immunol; 1979 Sep; 123(3):1285-8. PubMed ID: 469251
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Kinetic studies of the formation of the properdin system enzymes on zymosan: evidence that nascent C3b controls the rate of assembly.
    Nicholson A; Brade V; Lee GD; Shin HS; Mayer MM
    J Immunol; 1974 Mar; 112(3):1115-23. PubMed ID: 4811964
    [No Abstract]   [Full Text] [Related]  

  • 35. Guinea pig erythrocytes, after their contact with influenza virus, acquire the ability to activate the human alternative complement pathway through virus-induced desialation of the cells.
    Lambré CR; Kazatchkine MD; Maillet F; Thibon M
    J Immunol; 1982 Feb; 128(2):629-34. PubMed ID: 6459381
    [TBL] [Abstract][Full Text] [Related]  

  • 36. A monoclonal antibody that blocks the complement regulatory activity of guinea pig erythrocytes and characterization of the antigen involved as guinea pig decay-accelerating factor.
    Okada N; Tanaka H; Takizawa H; Okada H
    J Immunol; 1995 Jun; 154(11):6103-11. PubMed ID: 7538542
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Activation of the alternative complement pathway due to resistance of zymosan-bound amplification convertase to endogenous regulatory mechanisms.
    Fearon DT; Austen KF
    Proc Natl Acad Sci U S A; 1977 Apr; 74(4):1683-7. PubMed ID: 266208
    [TBL] [Abstract][Full Text] [Related]  

  • 38. A simple method for isolation of human properdin by affinity chromatography.
    Konno T; Hirai H
    J Immunol Methods; 1976; 12(1-2):47-55. PubMed ID: 792350
    [TBL] [Abstract][Full Text] [Related]  

  • 39. The role of properdin in the alternate pathway of complement activation.
    Götze O; Müller-Eberhard HJ
    J Exp Med; 1974 Jan; 139(1):44-57. PubMed ID: 4808709
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Complement-independent adherence of Escherichia coli to complement receptors in vitro.
    Fine DP; Harper BL; Carpenter ED; Davis CP; Cavallo T; Guckian JC
    J Clin Invest; 1980 Sep; 66(3):465-72. PubMed ID: 6105165
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.